What is the Descartes-08 Clinical Trial?
This Phase 1 study is evaluating the safety and feasibility of an investigational CAR T-cell therapy called Descartes-08 in eligible patients with active multiple myeloma.
Am I eligible?
You may be eligible if are 18 years and older and have:
- active multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) after at least 2 prior lines of therapy, or refractory at least 3 prior lines of therapy;
- measurable disease;
- adequate vital organ function; and
- no active infection.
Patients with prior CAR T-cell therapy and prior anti-BCMA therapy are allowed. Patients with plasma cell leukemia are not eligible.
Additional eligiblity criteria are available on ClinicalTrials.gov.
What Will Happen?
If you choose to participate and qualify, Descartes-08 will be custom-made for you from your own blood cells. Descartes-08 cells are CAR T-cells, which are T-cells that have been modified to attack myeloma (tumor) cells. To modify the cells, the Sponsor inserts new instructions into the T-cells. These instructions cause the cells to produce a new piece of cellular machinery called a CAR (Chimeric Antigen Receptor).
How will I receive Descartes-08?
Before you can receive Descartes-08 cells, you will receive three days of chemotherapy.
After the chemotherapy, Descartes-08 will be infused into your bloodstream. You will receive Descartes-08 in multiple doses over a week.
Will I be reimbursed for travel and accommodation?
Reimbursement may be provided for some types of travel and accommodation. Please contact study staff for details.
Billings Clinic Cancer Center
Center for Cancer and Blood Disorders
Georgetown University Lombardi Comprehensive Cancer Center
Virginia Cancer Specialists
Yale Cancer Center
New Haven, CT
Hackensack University Medical Center
West Cancer Center
University of Oklahoma Health Science Center
Oklahoma City, OK